[The role of radiotherapy in Graves' ophthalmopathy].
Radiotherapy is a well-established method of treatment for Graves' ophthalmopathy. The main rationale is its anti-inflammatory effect and the high radiosensitivity of T lymphocytes and orbital fibroblasts, which are important effectors in the immune reactions characterizing this disorder. Most centers use a dose of 20 Gy, ten daily doses of 2 Gy given over a period of 2 weeks. Overall favorable responses have been reported in 60% of cases. The best responses were noted for inflammatory signs and recent onset of extraocular muscle involvement. Radiotherapy is well tolerated and safe. A careful selection of patients is necessary. New randomized studies will have to evaluate new radiotherapy protocols with or without corticosteroids or medical immunosuppression.
Jaulerry
C
C
Service de Radiothérapie B, Institut Curie, 26, rue d'Ulm, 75231 Paris.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002386:Cataract / Q000209:etiology; D003131:Combined Modality Therapy; D000075202:Contraindications; D003930:Diabetic Retinopathy / Q000150:complications; D019583:Dose Fractionation, Radiation; D005347:Fibroblasts / Q000528:radiation effects; D006111:Graves Disease / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D011446:Prospective Studies; D011832:Radiation Injuries / Q000209:etiology; D011836:Radiation Tolerance; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D012164:Retinal Diseases / Q000209:etiology; D012189:Retrospective Studies; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000528:radiation effects; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents